Conditional Approval Pathways: The "Special" Case of Global Regenerative Medicine Regulation

Rejuvenation Res. 2017 Feb;20(1):1-3. doi: 10.1089/rej.2017.1932.

James A Smith^{1

2}, David A Brindley^{1

2

3

4

5

6}

¹ 1 Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Nuffield Orthopaedic Centre, University of Oxford , Oxford, United Kingdom .
² 2 The Oxford-UCL Centre for the Advancement of Sustainable Medical Innovation (CASMI), University of Oxford , Oxford, United Kingdom .
³ 3 Harvard Stem Cell Institute, Harvard University , Cambridge, Massachusetts.
⁴ 4 Department of Paediatrics, University of Oxford , Oxford, United Kingdom .
⁵ 5 Centre for Behavioural Medicine, UCL School of Pharmacy, University College London , London, United Kingdom .
⁶ 6 Stanford-UCSF FDA Centre for Regulatory Science and Innovation , San Francisco, California.

No abstract available

MeSH terms